Effect of Magnesium Supplementation on Circulating Biomarkers of Cardiovascular Disease
Abstract
Background: Magnesium supplementation may be effective for the prevention of cardiometabolic diseases, but mechanisms are unclear. Proteomic approaches can assist in identifying underlying mechanisms. Methods: We collected repeated blood samples in 52 individuals enrolled in a double-blind trial which randomized participants 1:1 to oral magnesium supplementation (400 mg magnesium / day in the form of magnesium oxide) or matching placebo for 10 weeks. Plasma levels of 91 proteins were measured in baseline and follow-up samples using the Olink Cardiovascular Disease III proximity extension assay panel, and modeled as arbitrary units in log2 scale. We evaluated the effect of oral magnesium supplementation on changes in protein levels and the baseline association between serum magnesium and protein levels. The Holm procedure was used to adjust for multiple comparisons. Results: Participants were 73% women, 94% white, and had a mean age of 62. Changes in proteins did not significantly differ between the two intervention groups after correction for multiple comparisons. The most statistically significant effects were on myoglobin [difference -0.319 log2 units, 95% confidence interval (CI) (-0.550, -0.088), p = 0.008], tartrate-resistant acid phosphatase type 5 [-0.187, (-0.328, -0.045), p = 0.011], tumor necrosis factor ligand superfamily member 13B [-0.181, (-0.332, -0.031), p = 0.019], ST2 protein [-0.198, (-0.363, -0.032), p =0.020], and interleukin-1 receptor type 1 [-0.144,…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 52 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.